Embla Medical hfOSSFF 92 Peter Lynch Fair Value is $2.10 as of Jul. 03, 2026, which is 28% below its 10-year median of 2.93. GuruFocus rates OSSFF with a GF Score™ of 92/100 and a GF Value™ of $5.29. The stock has 2 warning signs investors should review. Among 152 Medical Devices & Instruments companies, Embla Medical hf ranks worse than 56.58% on this metric.
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Here, as of today, Embla Medical hf's PEG is 1. Embla Medical hf's 5-Year TTM EBITDA Growth Rate is 10.41.
Embla Medical hf's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was $0.20. Therefore, the Peter Lynch Fair Value for today is $2.10.
As of today (2026-07-03), Embla Medical hf's share price is $4.15. Embla Medical hf's Peter Lynch fair value is $2.10. Therefore, Embla Medical hf's Price to Peter Lynch Fair Value Ratio for today is 1.97.
The historical rank and industry rank for Embla Medical hf's Peter Lynch Fair Value or its related term are showing as below:
OSSFF'
s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 1.75 Med: 2.93 Max: 58.37
Current: 1.8
During the past 13 years, the highest Price to Peter Lynch Fair Value Ratio of Embla Medical hf was 58.37. The lowest was 1.75. And the median was 2.93.
OSSFF's Price-to-Peter-Lynch-Fair-Value is ranked worse than 56.58% of 152
companies
in the Medical Devices & Instruments industry
Industry Median: 1.54
vs OSSFF: 1.80
Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.
Embla Medical hf (OTCPK:OSSFF) Peter Lynch Fair Value Explanation
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.
Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.
Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 10.41 instead of 15 in this case.
Embla Medical hf's Price to Peter Lynch Fair Value Ratio for today is calculated as
Price to Peter Lynch Fair Value
=
Share Price
/
Peter Lynch Fair Value
=
4.15
/
2.10
=
1.97
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Embla Medical hf Peter Lynch Fair Value Related Terms
Embla Medical hf Peter Lynch Fair Value Historical Data
* Premium members only.
The historical data trend for Embla Medical hf's Peter Lynch Fair Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSSFF vs ABT, SYK, MDT: Peter Lynch Fair Value Comparison
For the Medical Devices subindustry, Embla Medical hf's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Embla Medical hf Price-to-Peter-Lynch-Fair-Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Embla Medical hf's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:
* The bar in red indicates where Embla Medical hf's Price-to-Peter-Lynch-Fair-Value falls into.
Embla Medical hf's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.20.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.
If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.
If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.
Embla Medical hf (OSSFF) has a Peter Lynch Fair Value of $2.10 as of Jul. 03, 2026. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on Embla Medical hf and its competitors. This is 28% below median its historical median of 2.93. Over the past decade, Embla Medical hf's Peter Lynch Fair Value has ranged from 1.75 to 58.37. According to the industry distribution chart, Embla Medical hf ranks #86 out of 152 companies in the Medical Devices & Instruments industry, placing it in the top 56.6%.
Is Embla Medical hf's Peter Lynch Fair Value too high?
Embla Medical hf's current Peter Lynch Fair Value of $2.10 is 28% below median its 10-year median of 2.93. Over the past 10 years, this metric has ranged from a low of 1.75 to a high of 58.37. The Medical Devices & Instruments industry median Peter Lynch Fair Value is 1.54. Embla Medical hf's value of $2.10 is 36.4% above this industry median. Based on the distribution chart, Embla Medical hf ranks #86 out of 152 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Embla Medical hf has a GF Score™ of 92/100, reflecting its overall financial health beyond just this single metric.
How does Embla Medical hf's Peter Lynch Fair Value compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Embla Medical hf ranks #86 out of 152 companies for Peter Lynch Fair Value. This places Embla Medical hf in the lower half of its industry. The industry median Peter Lynch Fair Value is 1.54. Embla Medical hf's value of $2.10 is 36.4% above this benchmark. Historically, Embla Medical hf's own Peter Lynch Fair Value has ranged from 1.75 to 58.37 over the past decade. While the company's 10-year median is 2.93 vs. the industry median of 1.54, Embla Medical hf has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Peter Lynch Fair Value for a Medical Devices & Instruments company?
The median Peter Lynch Fair Value among Medical Devices & Instruments companies is 1.54, based on 152 companies in the industry. Companies in the top quartile (top 25%) have a Peter Lynch Fair Value significantly above this median, while those in the bottom quartile fall well below. However, Peter Lynch Fair Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Embla Medical hf's current Peter Lynch Fair Value of $2.10 is 36.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Peter Lynch Fair Value mean?
A high Peter Lynch Fair Value can signal that a stock is expensive relative to its fundamentals. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on Embla Medical hf and its competitors. For the Medical Devices & Instruments industry, the median Peter Lynch Fair Value is 1.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Embla Medical hf's current Peter Lynch Fair Value is $2.10, which is 28% below median its own 10-year median of 2.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Embla Medical hf stock overvalued right now?
Embla Medical hf (OSSFF) has a current Peter Lynch Fair Value of $2.10. The stock's GF Value™ is $5.29, compared to a current price of $4.15 — trading 21.6% below its estimated fair value. The current Peter Lynch Fair Value is $2.10, which is 28% below median its 10-year median of 2.93 and 36.4% above the Medical Devices & Instruments industry median of 1.54. Embla Medical hf's overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Peter Lynch Fair Value calculated?
Peter Lynch Fair Value is calculated from a company's financial statements. For Embla Medical hf (OSSFF), the current Peter Lynch Fair Value is $2.10 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Embla Medical hf (OSSFF) Overvalued in 2026?
Based on GuruFocus' analysis, Embla Medical hf stock appears to be undervalued.
The current stock price of $4.15 is trading 21.6% below its estimated GF Value™ of $5.29.
Key valuation signals for OSSFF:
Peter Lynch Fair Value: $2.10 (28% below median its 10-year median of 2.93)
GF Value™: $5.29 vs. price of $4.15 (21.6% below fair value)
Industry Position: 36.4% above the Medical Devices & Instruments median (#86 of 152)
No single metric tells the full story. See the OSSFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Embla Medical hf operates as an orthopedic products company specializing in the design, development, manufacturing and sales of prosthetics and bracing & supports products. The company also provides patient care through a network of Orthotic and Prosthetic (O&P) facilities. It sells its products in multiple countries, with Europe and North America representing its principal markets. The company operates within three business segments: Prosthetics & Neuro Orthotics, Bracing & Supports and Patient Care. The majority of the company's revenue is derived from the Prosthetics & Neuro Orthotics, which includes products designed for users with varying mobility needs, ranging from lower-activity applications to solutions intended for more active use.
92GF Score
Get the complete analysis for OSSFF
Peter Lynch Fair Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSSFF has been successfully added to your 
